Bone mass density, fracture history, self-reported osteoporosis as proxy variables for estrogen and the risk of non-small-cell lung cancer—A population based cohort study, the HUNT study: Are proxy variables friends or faults?

Hatlen, Peter; Forsmo, Siri; Carlsen, Sven Magnus; Amundsen, Tore

doi:10.1016/j.lungcan.2013.04.001

Cited by 7 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, high bone density disorders from the immune disease class were strongly enriched in lung squamous cell carcinoma (Lung-SCC; Log2OR = 5.39, P = 3.45 × 10 −2 ). Interestingly, the comorbidity relationship between bone mineral density disorder and lung cancer has previously been observed 19, 20 .…”

Section: Resultsmentioning

confidence: 93%

Systematic analysis of disease-linked rare germline variants reveals new classes of cancer predisposing genes

Song

Koh

Kim

et al. 2023

Preprint

View full text Add to dashboard Cite

Despite recent insights into cancer predisposition genes (CPGs), the contribution of rare germline variants to carcinogenesis remains unclear. Here, we examine the enrichment of rare germline variants in Mendelian disease-associated genes using PCAWG and the 1,000 Genomes Project. Using an integrative approach that considers disease classes, cellular pathways, and tissue expression profiles, we find that subsets of Online Mendelian Inheritance in Man (OMIM) genes are strong candidate CPGs. These genes were classified into five clusters suggesting diverse mechanisms underlie tumor progression. We further analyzed PAH gene which shows the strongest prevalence of rare germline variants in cancers (2.2%) compared to controls (0.7%). This enrichment was validated in two independent cancer cohorts and present the possibility of tumorigenesis by contributing immune-associated pathways. Our data argue that rare germline variants of Mendelian disease-associated genes contribute to cancer progression and suggest new CPG classifications that may underlie diverse tumorigenesis mechanisms.

show abstract

Section: Resultsmentioning

confidence: 93%

Systematic analysis of disease-linked rare germline variants reveals new classes of cancer predisposing genes

Song

Koh

Kim

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The random effects model was performed for the meta-analysis of pooled quantitative data due to statistically significant heterogeneity across the included studies (P < 0.05 or I 2 > 50%). In this pooled analysis of serum CYFRA 21-1 level in all NSCLC patients showed that the pooled sensitivity, specificity, PLR, NLR, and DOR was 0.60 (95% confidence interval (CI) 0.58, 0.61), 0.90 (95% CI 0.89, 0.91), 5.93 (95% CI 4.10, 8.57), 0.40 (95% CI 0.32, 0.50), and 16.17 (95% CI 10.04, 26.04), respectively, and the area under the SROC curve was 0.8676 (Q*=0.7981) (Figure 1).…”

Section: Resultsmentioning

confidence: 99%

“…All statistical tests were two sided, and P < 0.05 was considered to be statistically significant. The heterogeneity test was performed through Cochran’s Q statistics and I 2 test. If there was significant heterogeneity with P < 0.05 or I 2 > 50%, the random effects model was chosen to obtain the combined effect value; otherwise, the fixed effects model was adopted (P ⩾ 0.05 or I 2 ⩽ 50%).…”

Section: Methodsmentioning

confidence: 99%

“…The heterogeneity test was performed through Cochran’s Q statistics and I 2 test. If there was significant heterogeneity with P < 0.05 or I 2 > 50%, the random effects model was chosen to obtain the combined effect value; otherwise, the fixed effects model was adopted (P ⩾ 0.05 or I 2 ⩽ 50%). Also, a subgroup analysis was performed based on the regional differences (Asian area vs. Western area), study types (prospective vs. retrospective study) and the detection methods of serum CYFRA21-1 (ECLIA vs. EIA, ELISA, and IRMA), investigating the effect of the above factors on the results of sensitivity, specificity, PLR, NLR, and DOR in different subtypes of NSCLC.…”

Section: Methodsmentioning

confidence: 99%

“…Lung cancer is one of the leading causes of death throughout the world 1 and has the highest mortality of all cancers. 2 The prognosis of lung cancer is poor and less than 15% of patients can survive 5 years after diagnosis. The lack of efficient diagnostic methods and successful treatment for early detection and metastatic disease have caused the poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: A meta-analysis

Wang

Yin

et al. 2019

Int J Biol Markers

View full text Add to dashboard Cite

Objective: The aim of the study was to evaluate the diagnostic value of soluble fragment of cytokeratin 19 (CYFRA21-1) tests in detecting non-small cell lung cancer (NSCLC), including squamous cell carcinoma, lung adenocarcinoma, and large cell carcinoma. Methods: The relevant studies were identified from PubMed, Embase and the Cochrane Library before November 2018. Summary estimates for sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of CYFRA21-1 tests for the diagnosis of NSCLC were calculated using the random effects model. A summary receiver operating characteristic (SROC) curve was used to assess the overall effectiveness of the test. Meta-DiSc 1.4 and Stata11.0 were applied to the statistical analysis. Publication bias was detected using Egger’s test. Results: A total of 22 studies consisting of 7910 NSCLC patients (squamous cell carcinoma/lung adenocarcinoma/large cell carcinoma) and 2630 benign lesions patients that met the inclusion criteria were included. The meta-analysis showed that CYFRA21-1 tests had a relatively high accuracy for squamous cell carcinoma detection and a lower accuracy for lung adenocarcinoma detection. The overall sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of CYFRA21-1 tests for squamous cell carcinoma detection were 0.72 (95% confidence interval (CI) 0.70, 0.74), 0.94 (95% CI 0.92, 0.95), 9.73 (95% CI 7.06, 13.40), 0.37 (95% CI 0.29, 0.47), and 27.30 (95% CI 17.68, 42.16), respectively. The area under the SROC curve was 0.9171 (Q* = 0.8500). No publication bias was tested in the squamous cell carcinoma (P = 0.567) and lung adenocarcinoma (P = 0.378) groups. Conclusions: CYFRA21-1 tests might be appropriate for detecting squamous cell carcinoma.

show abstract

Bone Disorders in Cancer

Oleson

2017

Osteoporosis Rehabilitation

View full text Add to dashboard Cite

Bone mass density, fracture history, self-reported osteoporosis as proxy variables for estrogen and the risk of non-small-cell lung cancer—A population based cohort study, the HUNT study: Are proxy variables friends or faults?

Cited by 7 publications

References 42 publications

Systematic analysis of disease-linked rare germline variants reveals new classes of cancer predisposing genes

Systematic analysis of disease-linked rare germline variants reveals new classes of cancer predisposing genes

CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: A meta-analysis

Bone Disorders in Cancer

Contact Info

Product

Resources

About